RxDoctor Payments Data

Krysta Contino, MD

Gastroenterology · Camden, NJNPI 1740695782

Payments from drug & device makers

$1,983in general payments, 2019–2025

Across 63 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$399
  • Takeda Pharmaceuticals U.S.A., Inc.$322
  • AbbVie$267
  • Covidien LP$190
  • Romark Laboratories, LC$163
  • Fujifilm Healthcare Americas Corporation$145
  • plus $499 from 12 others

What the payments were for

  • Food & beverage$1,88495%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,983 in reported general payments places this provider in the 45th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$77,817
Medicare patients
280
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin37$117,729
CreonLipase/Protease/Amylase27$95,161
LinzessLinaclotide60$32,726
TrulancePlecanatide27$16,518
Omeprazole319$3,182
Famotidine242$2,226
Lubiprostone18$1,798
Pantoprazole Sodium153$1,721
Lactulose60$1,399
Sucralfate31$1,321
Ursodiol15$1,318
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl46$654
Dicyclomine Hcl25$596
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl38$538
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg17$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$73$134,24764 claims
AbbVieCreon, Linzess$267$127,88787 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →